Myeloablative Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Consolidation Treatment for Pediatric Malignancy- Single Institute Experience

摘要

Mixed donor chimerism is a risk factor for graft loss andrelapse of the original disease. This is treated with withdrawal of immu-nosuppressive agents and donor lymphocyte infusion (DLI). DLI is a form ofimmunotherapy which has a therapeutic role in relapse, pre-emptive usein patients considered to be at high risk of relapse, and in case of mixedchimerism 1 .